SoloPak Obtains Rights to Ganite

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed an agreement with Sloan-Kettering Institute for Cancer Research to acquire the exclusive worldwide rights to gallium nitrate (Ganite), which was FDA approved in 1991 for the treatment of acute hypercalcemia in cancer patients and had been manufactured by Fujisawa USA (Deerfield, Ill).

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signedan agreement with Sloan-Kettering Institute for Cancer Researchto acquire the exclusive worldwide rights to gallium nitrate (Ganite),which was FDA approved in 1991 for the treatment of acute hypercalcemiain cancer patients and had been manufactured by Fujisawa USA (Deerfield,Ill).

The agreement involves a grant of SoloPak equity to the Instituteand a commitment of funds from SoloPak to complete clinical trials.

Over the next 2 to 3 years, SoloPak plans to seek approval ofgallium nitrate for the treatment of chronic hypercalcemia andbone metastases in cancer patients, and to launch clinical trialsof the agent in Paget's disease and osteoporosis.

Articles in this issue
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Related Content
FDA Approves Alectinib for Early-Stage ALK+ NSCLC

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024
Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer

Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer

April 18th 2024
Article

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.

FDA Approves Pegulicianine-Based Imaging for Breast Cancer Surgery

April 18th 2024
Article

Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.